Tony Cantwell, MD
Urology · Daytona Beach, FLNPI 1316978737
Payments from drug & device makers
Across 235 payments — averaging $138.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$28K
- Astellas Pharma US Inc$700
- Coloplast$642
- Johnson & Johnson$487
- AbbVie$338
- Cook Medical LLC$272
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,452100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 7 | $28,212 |
| Astellas Pharma US Inc | 45 | $700 |
| Coloplast | 15 | $642 |
| Johnson & Johnson | 30 | $487 |
| AbbVie(2 entities) | 16 | $338 |
| Cook Medical LLC | 9 | $272 |
| Dendreon Pharmaceuticals LLC | 10 | $215 |
| Pfizer | 13 | $197 |
| Endo Pharmaceuticals Inc. | 7 | $135 |
| Boston Scientific | 2 | $131 |
| Teleflex LLC | 5 | $107 |
| Bayer | 5 | $105 |
| Novartis | 6 | $97 |
| Merck | 5 | $93 |
| Amgen | 5 | $78 |
| Urogen Pharma, Inc. | 4 | $65 |
| Tolmar Pharmaceuticals, Inc. | 4 | $63 |
| Accord Healthcare, Inc. | 2 | $53 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Sun Pharmaceutical Industries Inc. | 3 | $52 |
| Ferring Pharmaceuticals Inc. | 3 | $52 |
| Myriad Genetic Laboratories, Inc. | 2 | $48 |
| Tolmar, Inc. | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Dentsply IH Inc. | 3 | $42 |
| Foundation Medicine, Inc. | 2 | $41 |
| Verity Pharmaceuticals Inc. | 3 | $40 |
| Myovant Sciences Inc. | 3 | $37 |
| AstraZeneca | 2 | $32 |
| Antares Pharma, Inc. | 2 | $31 |
| Baxter Healthcare | 1 | $24 |
| Endo USA, Inc. | 1 | $21 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Immunitybio, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Mindray DS USA, Inc. | 1 | $13 |
| Axonics, Inc. | 1 | $13 |
| Healthtronics Stone Solutions, LLC | 1 | $8 |
| Urogpo LLC | 2 | $0 |
| SN Holdings, LLC | 5 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Porges Coloplast$136
- Orchestra$131
- LithoVue$114
- Cook Medical Lasers$107
- SPEEDICATH$107
How this compares
$32,633 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 27 | $377,149 |
| XtandiEnzalutamide | 11 | $160,394 |
| OrgovyxRelugolix | 41 | $105,177 |
| MyrbetriqMirabegron | 60 | $37,829 |
| ElmironPentosan Polysulfate Sodium | 38 | $29,406 |
| Tamsulosin Hcl | 622 | $9,953 |
| Desmopressin Acetate | 80 | $6,692 |
| Testosterone | 18 | $5,990 |
| Potassium Citrate ErPotassium Citrate | 113 | $5,348 |
| Finasteride | 318 | $4,937 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 115 | $3,103 |
| Dutasteride | 63 | $2,812 |
| NitrofurantoinNitrofurantoin Macrocrystal | 73 | $1,963 |
| Cephalexin | 215 | $1,927 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 77 | $1,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $487 | $377,14927 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $700 | $198,22371 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $52 | $105,17741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.
Other urology in Daytona Beach
- Evan FynesDaytona Beach$324K
- Samuel LawindyDaytona Beach$268K
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
- Graham GreeneLakeland$2.5M
- Scott SellingerTallahassee$2.3M
- Fernando BiancoHialeah$2.2M
- Osvaldo PadronTampa$1.3M
- Mark Anthony GonzalgoMiami$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.